Research programme: anti-infectives - Xellia Pharmaceuticals

Drug Profile

Research programme: anti-infectives - Xellia Pharmaceuticals

Alternative Names: XEL 1001; XEL 1002; XEL 1003; XEL 1004; XEL 1005; XEL 1007; XEL 1009

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xellia Pharmaceuticals
  • Developer SINTEF Materials and Chemistry; Statens Serum Institut; Xellia Pharmaceuticals
  • Class Antibacterials; Polymixins
  • Mechanism of Action Cell membrane modulators; Cell wall inhibitors; Lipopolysaccharide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis-associated respiratory tract infections; Gram-positive infections
  • No development reported Gram-negative infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Gram-negative-infections in Norway (Parenteral)
  • 21 Dec 2015 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in Norway (Parenteral) before December 2015
  • 21 Dec 2015 Preclinical trials in Gram-positive infections in Norway (Parenteral) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top